Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
Recruiting now · Phase 4
Conditions studied: Metabolic Syndrome
In brief
Background. The prevalence of type 2 diabetes mellitus (T2D) in the world is constantly increasing. Treatment of T2D is complicated by arterial hypertension and obesity (metabolic syndrome - MS). Cardiovascular complications are the main cause of death in patients with MS. Objective weight loss improves clinical and laboratory parameters in patients with T2D and hypertension. Purpose: To study lifespan, glycemic and lipid metabolism, quality of life, and cost-effectiveness of pharmacologic, surgical, and dietetic weight loss methods in obese patients with MS at 24 weeks in a comparative clinical trial. Methods: 1. st stage - Study design: An open pilot prospective clinical trial. The study included 71 adult patients with T2D and hypertension for the Ramadan fast's (RF) weight loss. 2. nd stage - Study design: A 24-week open label, prospective, multicenter, comparative clinical trial with the intention-to-treat analysis. Participants. Totally 150 adult patients with MS aged 35-65 years and with BMI≥27 kg/m2 for Asian will be included. They will be distributed in three comparative groups: drug treatment, surgery and diet. Primary endpoints: weight loss, fasting blood glucose, blood insulin level, systolic/diastolic BP. Secondary endpoints: blood lipids, heel bone mineral density (HBMD), and ejection fraction (EF). Expected results: A prospective multicenter clinical study will provide comparative results on life expectancy, glycemic and lipid metabolism, quality of life, cost-effectiveness of pharmacological, bariatric and dietary methods of weight loss in patients with obesity, T2D and hypertension. As a result of the research, the following will be published: 1. at least three articles and/or reviews in peer-reviewed scientific publications indexed in the Science Citation Index Expanded of the Web Of Science database and/or having a Cite Score percentile in the Scopus of at least 50; 2. at least 1 patent for an invention (including a positive decision on it).
Key facts
- Study ID
- NCT06410352
- Run by
- University Medical Center, Kazakhstan
- People needed
- 220
- Starts
- 2024-03-01
- Expected to finish
- 2026-07-31
- Last updated by the study team
- 2025-11-26
Who can join
Age: 35 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- written informed consent;
- T2D≥3-year with glucose lowering therapy including insulin;
- 35-55 years old;
- BMI≥27 kg/m2 for both sex, for Asian ethnicity;
- ongoing treatment with antihypertensive treatment;
- weight loss 15-20% at baseline and dynamic follow-up up to 24 weeks.
You may not qualify if…
- T1D;
- <34 age >56 years old;
- unstable cardiac disorders (New York Heart Association class IV heart failure, refractory angina, uncontrolled arrhythmias, critical valvular heart disease, or severe uncontrolled hypertension);
- glomerular filtration rate <30 mL/min and/or dialysis within 14 days before screening; • malignancy within the past 5 years;
- gestation or lactation;
- hereditary diseases;
- known hypersensitivity to any of the test substances.
Where it is running
- Kuat Pernekulovich Oshakbayev — Astana, Astana, Kazakhstan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.